Join to View Full Profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Dr. Nakazawa is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Michael Nakazawa is an oncology specialist with a subspecialty in sarcoma, based in Houston, TX. He completed his fellowship in Hematology and Medical Oncology at the University of Texas Health Science Center in collaboration with MD Anderson Cancer Center and holds a PhD in Cell and Molecular Biology from the University of Pennsylvania. Currently, he serves as an Assistant Professor at the University of Texas M.D. Anderson Cancer Center and previously completed his Internal Medicine residency at UCLA Health. Dr. Nakazawa has experience in molecular biology and has published several research articles focusing on sarcoma and related therapies. In recognition of his contributions, he received the Conquer Cancer Young Investigator Award from ASCO in 2022.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2020 - 2023
Perelman School of Medicine at the University of PennsylvaniaClass of 2017
University of PennsylvaniaPhD, Cell and Molecular Biology, 2011 - 2015
Certifications & Licensure
TX State Medical License 2021 - 2026
CA State Medical License 2018 - 2020
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- K12 Award NIH, 2024
- Conquer Cancer Young Investigator Award ASCO, 2022
Publications & Presentations
PubMed
- 2 citationsLoss of the DNA Repair Gene RNase H2 Identifies a Unique Subset of DDR-Deficient Leiomyosarcomas.Michael S Nakazawa, Ian M Silverman, Victoria Rimkunas, Artur Veloso, Dominik Glodzik
Molecular Cancer Therapeutics. 2024-07-02 - 1 citationsHigh-Grade Pleomorphic Sarcomas Treated with Immune Checkpoint Blockade: The MD Anderson Cancer Center Experience.Lewis F Nasr, Marianne Zoghbi, Rossana Lazcano, Michael Nakazawa, Andrew J Bishop
Cancers. 2024-05-01 - 1 citationsUtility of Clinical Next Generation Sequencing Tests in KIT/PDGFRA/SDH Wild-Type Gastrointestinal Stromal Tumors.Ryan A Denu, Cissimol P Joseph, Elizabeth S Urquiola, Precious S Byrd, Richard K Yang
Cancers. 2024-04-27
Press Mentions
Understanding Adult Rhabdomyosarcoma: Types, Prognosis and TreatmentJanuary 16th, 2025
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
